SEARCH RESULTS FOR:
Eduardo Ruiz
GENERAL MANAGER, AMPHOS21
"Standards for tailings facilities are definitely improving with more automatization, control and monitoring, so this is a segment where we are going to see a lot of work in the future."
Joshua Olmsted
PRESIDENT AND CHIEF OPERATING OFFICER-AMERICAS, FREEPORT-MCMORAN
Chile Mining 2021 - Digital Interactive
Freeport-McMoRan speaks with GBR about its intentions for its El Abra mine in Chile.
Dan Wilton
CEO, FIRST MINING GOLD CORP.
First Mining Gold explains how it is developing its Springpole and Goldlund assets.
Miguel Ángel Arenas
GENERAL MANAGER, GEOTEC
Geotec speaks to GBR about the current environment for drilling companies in Peru.
Robert E. Landry
EXECUTIVE VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER, REGENERON
Regeneron explains how its capabilities for target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional drug discovery and development process.
Don Duval
CEO, NORCAT
NORCAT explains to GBR how it is helping companies to bring new technologies to the mining industry.
Darío Barros Izquierdo
GENERAL MANAGER, ECHEVERRIA IZQUIERDO MONTAJES INDUSTRIALES
Chile Mining 2021 - Digital Interactive
"The challenge for the construction sector is to not overreact to any situation and also take a longer-term view, using this time as an opportunity to be creative and innovative, incorporate new technology and be more productive and sustainable."
Donna LaVoie
PRESIDENT & CEO, LAVOIEHEALTHSCIENCE
LaVoie Health Science explains how the communication requirements for Biotech companies have evolved significantly.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
